Related Experiment Video

Updated: Aug 23, 2026

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
07:42

Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates

Published on: October 18, 2018

Dihydropyridine calcium channel blockers: basic pharmacological similarities but fundamental therapeutic differences

Peter A Meredith1, Henry L Elliott

  • 1Division of Cardiovascular and Medical Sciences, Gardiner Institute, Western Infirmary, Glasgow, Scotland, UK. p.a.meredith@clinmed.gla.ac.uk

Journal of Hypertension
|August 18, 2004
PubMed

Insights

Calcium channel blockers (CCBs) effectively reduce cardiovascular risks in hypertension. However, not all CCBs are equivalent, especially within the dihydropyridine class, necessitating careful consideration of their distinct profiles.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine
  • Clinical Trials

Background:

  • Calcium channel blockers (CCBs) are widely used for hypertension and coronary artery disease.
  • Outcome trials suggest CCBs reduce cardiovascular morbidity and mortality.
  • A common misconception is that all CCBs have similar therapeutic effects.

Purpose of the Study:

  • To address the misconception that all CCBs are therapeutically equivalent.
  • To highlight the significant differences within the dihydropyridine CCB subclass.
  • To emphasize the need for caution when assuming equivalence in once-daily CCBs.

Main Methods:

  • Review of clinical pharmacological differences between CCB classes.
  • Analysis of pharmacokinetic and pharmacodynamic profiles.
  • Evaluation of therapeutic profiles and potential long-term outcome differences.

Main Results:

  • Significant pharmacological differences exist between rate-limiting CCBs (verapamil, diltiazem) and dihydropyridines.
  • Substantial variations in pharmacokinetic and pharmacodynamic properties are observed within the dihydropyridine group.
  • These differences suggest distinct therapeutic profiles and potential variations in long-term treatment outcomes.

Conclusions:

  • Generalizing outcome study findings across all CCBs is a misconception.
  • Dihydropyridine CCBs exhibit significant inter-agent differences.
  • Caution is advised when assuming equivalence in once-daily dihydropyridine CCBs regarding duration and efficacy.

More Related Videos

Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents10:53

Isolation of Human Atrial Myocytes for Simultaneous Measurements of Ca2+ Transients and Membrane Currents

Published on: July 3, 2013

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antihypertensive Drugs: Thiazide-Class Diuretics01:15

Antihypertensive Drugs: Thiazide-Class Diuretics

Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...